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Abstract
Background: To compare the recent de-escalations rates with a six-
year earlier study, and mortality associated with de-escalation.
Methods: A prospective multicenter study including septic patients, 
all were on broad-spectrum antimicrobials (BSA). Excluded from the 
study patients on antimicrobial prophylaxis, and patients without a 
microbiological diagnosis, or bacteria were solely BSA-susceptible. The 
study team made recommendations for antimicrobials de-escalation 
to the treating physician(s) must an opportunity loomed. 
Results: 182 patients were available for analysis. De-escalation was 
achieved in 43 (24%) patients. The clinical diagnoses, comorbidities, 
commonly used antimicrobials, the microbiological diagnoses were 
not different between the two groups (patients with and without de-
escalation). Logistic regression analysis showed no correlation between 
bacterial species and de-escalation (Nagelkerke R2 = 0.076). Relapsing 
sepsis and reinfection were not different (P > 0.05).The in-hospital 
mortality rates for the de-escalated patients were lower (P = 0.015)
but not on day 30 (P = 0.354). The length of the ICU stay and ward 
stay were not different (P >0.05), but more de-escalated patients were 
discharged home from the ICU (P = 0.034), however, patients without 
de-escalation were discharged more from the ward (P = 0.002).
Conclusion: De-escalation rates increased within six years from 6.7%- 
24% (P = 0.000), with added benefits of shorter ICU stay and less 
in-hospital mortality
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Introduction
De-escalation is one of the paradigms of a mul-
tifaceted antimicrobials stewardship (AMS) that 
avoids unnecessary use of the broad-spectrum 
antimicrobials (BSA ) and their extended duration, 
it is mostly based on a microbiological diagnosis 
and susceptibility [1-4]. The old dictum “hit hard 
and hit fast” is a principle in treating patients with 
severe sepsis, it focuses on treating patients appro-
priately and early [5, 6], this would help improving 
outcomes without undue delay at a time before 
a microbiological diagnosis is available [7]. With 
the rapid evolution of the diagnostic methods 
with rapid bacterial identification and susceptibi-
lity patterns, de-escalation as a concept must be 
a common practice, especially it is known to a 
meliorate the BSA sustained pressure upon bac-
teria, and cause less resistance [8], and adapting 
to a culture-driven antimicrobial therapy became 
evidently beneficial; the benefits of de-escalation 
are being frequently cited for lowering treatment 
costs, reducing the chances of inducing resistant 
among bacterial strains, reducing antimicrobials’ 
toxicity and collateral damage of BSA [9-12], none 
the less many physicians do not feel comfortable 
with de-escalation: “why change, it works” [13-
14]. Earlier in Amman - Jordan, we published a 
study that showed poor compliance with de-es-
calation. Now, we aim to re-evaluate the rates of 
the antimicrobials de-escalation in the same hos-
pitals and almost the same staff after the accredi-
tation by the Joint commission International (JCI) 
whom surveillance includes elements of a working 
stewardship program [15-16]. We plan to test the 
hypothesis that JCI-driven recommendations con-
vince the hospitals and the physicians in adopting 
the practice of de-escalation for being an impor-
tant element of antimicrobial stewardship leading 
to a better patients’ care, and help in lowering 
resistance rates, cost and mortality. Although there 
is no adequate information from controlled trials 
so far, but observational ones revealing a better 
outcome in the de-escalated patients [17-20]. Our 
study aims to respond to skepticism, and if prove 
useful, it may encourage the practicing physician 
to de-escalate to a focused antimicrobial therapy 
when an opportunity arises.
Materials and Methods
Setting 
A multicenter prospective study held in Amman – 
Jordan, between December 2014 to March 2019. It 
was conducted in three private hospitals; two tea-
ching; The Specialty (Al Takhassusi) and Jordan Hos-
pital and one community service hospital; Al Khalidi, 
with a total of 650 beds and 52 ICU beds. The three 
hospitals have no antimicrobials restriction policy. 
The internal review boards of each hospital appro-
ved the study. Daily charts review on antimicrobial 
prescription, changes in prescription and progress 
of patients (see inclusion criteria) were monitored. 
Each study team in the teaching hospitals included 
a clinical pharmacist and a medical resident, and cli-
nical pharmacists in the community hospital. Follow 
up on the microbiological data, diagnosis accuracy 
according to CDC published criteria for nosocomial 
infections and the microbiologically documented 
diagnoses for admitted patients with community-
associated infections were revised. The clinical phar-
macist and/or the medical residents suggested de-
escalation to the attending physician when there 
was an opportunity, the attending physician is the 
responsible prescriber for accepting or rejecting the 
de-escalation or escalating the regimen. Thirty days 
after the patients discharge, they were followed up 
by phone calls for mortality.
Inclusions and exclusion criteria
Patients were included if they were diagnosed to 
have documented sepsis, or septic shock associa-
ted with community-acquired pneumonia (CAP), 
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ventilator-associated pneumonia (VAP), catheter-
associated urinary tract infections (CAUTI), severe 
urinary tract infections (UTI), central line-associated 
blood stream infection (CLABSI), bacteremia of un-
defined source and blood cultures were available, 
skin and skin structure infection (SSTI) intra-abdo-
minal infection (IAI) and meningitis, for which BSA 
agents as mono-therapy or in combination were 
prescribed [21]. Failure to de-escalate was consi-
dered for patients when a bacterial culture and 
its susceptibility were known, and the causative 
bacteria could be treated with a focused narrow-
spectrum antimicrobial, but the treating physician 
continued using the initial or an alternative BSA 
monotherapy or in combination despite the clinical 
pharmacist advice. Excluded patients those who 
were not started on BSA agents, were on antimi-
crobial prophylaxis, there was no clear indication 
for the use of BSA agents, and all septic patients 
whom do not have a microbiological diagnosis. 
The following available agents were considered 
BSA agents: carbapenems, β-lactam β-lactamase 
inhibitors, glycylcyclines, respiratory quinolones 
and the parenteral third and fourth generations’ 
cephalosporins, and combination antimicrobials 
therapies prescribed in treating seriously sick pa-
tients and intended to provide BSA coverage with 
or without vancomycin or teicoplanin.
Outcome measures
The primary outcome measure is to evaluate the 
difference in the rates of de-escalated patients from 
BSA to an appropriate narrow spectrum agent and 
comparing the rates with a previous study we pu-
blished earlier in this regard [15]. And to estimate 
the mortality rates associated with de-escalation 
compared with patients without de-escalation. 
Secondary outcome measures were if physicians’ 
attitude were influenced by patients’ admission lo-
cation, comorbidities, clinical diagnosis and micro-
biological diagnosis.
Statistical analysis
Rates of the antimicrobials de-escalation were cal-
culated, t-student test was used to estimate the 
difference between the meansand proportions. Se-
condary outcomes wereanalyzed by Fischer’s exact 
test or χ2 to demonstrate if there were differences 
among different estimators. Two-sided P≤ 0.05 is 
considered significant. Logistic regression analysis 
was used for border line P-value to support relation 
between the tested variable and the de-escalation. 
Data were analyzed using SPSS (IBM corporation, 
version 22, 2018).
Results
There were 182 patients available for analysis. De-
escalation was achieved in 43(24%) patients. Males 
were 109 (59%), there was no significant gender 
difference between both de-escalation and without 
de-escalation groups (P = 0.375). The clinical diag-
noses and comorbidities were not significantly di-
fferent between the two groups, as well as the 
commonly used antimicrobials (P > 0.05). The mi-
crobiological diagnoses showed no significant diffe-
rence (P = 0.05), logistic regression analysis showed 
no correlation between bacterial species and the 
de-escalation (Nagelkerke pseudo-R2 = 0.076).Re-
lapsing sepsis and reinfection in both groups were 
few in numbers and no significant differences were 
detected (P > 0.05), though all the few relapsed 
cases and most cases in the reinfection were in pa-
tients without de-escalated (Table 1).
Table 1.  Demography and characteristics of patients 
in the de-escalation study .
Characteristic
De-
escalated
Not De-
escalated P 
-value
N (%) N (%)
Number of Patients 
(N = 182) 43 (24) 139 (76)
Age mean* 
(Years)
61.66 63.45 0.559
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Characteristic
De-
escalated
Not De-
escalated
P 
-value
Gender1
Males 23 86
0.375
Females 20 53
Clinical Diagnosis
Bacteremia 12 38
0.464
CAP 3 14
Sepsis/undefined 7 37
UTI 15 39
Others 6 11
Comorbidities
DM 26 96
0.739
COPD/Chronic lung disease 3 24
Skin disease 1 7
Hematological malignancy 8 9
Solid Malignancy 5 18
Immunosuppressive states 10 32
Others Comorbidities** 29 91 0.128
Microbiological diagnosis
Enterobacteriaceae 23 51
0.05
S. aureus 7 25
Lactose non fermenters 3 20
Enterococci 4 4
N/A 6 39
Commonly used antimicrobials*
Carbapenems 25 75
≥ 0.2
Pipracillin/tazobactam 11 24
Cephalosporines 
(3rd and 4th)
7 17
Tigecycline 0 5
Colistin 0 1
Glycopeptides 7 29
Quinolones 1 33 0.001
Relapse
Clinical 2 3
> 0.3
Microbiological 0 2
Microorganism 0 1
Site2 1 3
Reinfection
Acinetobacter spp. 0 2
0.742Enterococci 0 1
Others 0 1
*P-value was tested by ANOVA and was significant. 
**: Hypertension, renal failure, CVA, CAD, heart failure and others. 
1: By Fisher exact test, 2-sided. 2: 1 VAPin each arm, 1 undefined 
sepsis and 1 bacteremia.
The in-hospital mortality rates for the de-esca-
lated patients were significantly lower than those 
without de-escalation (P = 0.029), but there was 
no mortality difference on day 30 (P = 0.503) (Fi-
gure A). Patients who were escalated have higher 
in-hospital mortality than those without de-esca-
lation (P = 0.000), and tendency towards higher 
mortality onday 30 (P = 0.051) (Figure B). The 
length of the ICU stay and the ward saty were 
Figure A, B:  In-hospital and 30-days mortality ra-
tes for patients.
A) with and without de-escalation; B) for escalation and without escalation. 
Patients. De-escalated number of patients = 42, and without de-escalation 
= 139. Escalated number of patients = 52 and without escalation = 130. 
Note that the 130 without escalation have included those with de-escalation 
= 43. P-value significance was tested by 2-sided Fisher’s exact test
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not significantly different (P >0.05) between the 
two groups, but significantly more de-escalated 
patient were discharged home directly from the 
ICU (P = 0.034), however, in the ward the patients 
without de-escalation were discharge sooner (P = 
0.002) (Table 2).
Discussion
The concept of de-escalation came into practice 
as BSA agents were found not devoid of flaws 
when used appropriately, not to mention the un-
justified regimen, duration, dose and frequency of 
a therapeutic regimen, where CDI, MRSA, VRE, 
ESBL and CRE are becoming the major culprit of 
the wide “and indiscriminate” use of BSA agents 
[22-27]. The aim of this study was to evaluate the 
changing rates of de-escalation and the associated 
mortality, after the JCI enforcement on the anti-
microbial stewardship. There was an improvement 
in the rates of de-escalation, it significantly soared 
from 6.7% to 24% (P = 0.000) in six years (2012 
to 2018), though the absolute rise in number is a 
modest one, but it was almost quadrupled, this 
is an encouraging step to keep momentum for 
education, ward suggestions and administrations 
support in the pursue of better antimicrobial utili-
zation. Recorded rates for de-escalation in several 
countries of the world may reach 32.1%-51%, hig-
her than our improved rates [28-30].
The in-hospital mortality was lower in the de-
escalated patients (P = 0.029), the results of a pre-
vious work demonstrated that de-escalation in se-
vere sepsis and septic shock was safe with a lower 
mortality [19, 31] even in culture negative septic 
patients with healthcare-associated pneumonia 
[32]. Escalating the antimicrobial therapy in a sub-
set of patients had significantly higher in-hospital 
mortality (P =0.000) and tendency towards higher 
mortality on day 30 (P = 0.051), possibly because 
the treating physicians were hesitant to de-esca-
late, on the contrary, antimicrobial treatment was 
escalated in the very sick patients, following the 
idea “more is better”. However, the addition of 
another antimicrobial did not alter the outcome 
of those subset of patients, and they had a higher 
mortality compared with patients without escala-
tion, similar to was found earlier that escalation 
were associated with a higher mortality in non 
bacteremic patients with pneumonia, though it 
was confounded by a higher inappropriate thera-
py [33]. Notably, the length of ICU Stay and ward 
stay were not different for both groups (P > 0.05), 
but the hospital discharge were significantly better 
for patients with de-escalation from the ICU and 
from the medical ward at home (P < 0.05), this also 
Table 2.  The means of the length of stay in the ICU and the hospital ward for patients with de-escalation 
and without de-escalation .
Characteristic
The mean of the days and the (number of patients)*
P-Value De-escalated Not De-escalated
N % N %
Length of Stay (ICU) 4.81 42 5.7 137 0.584
Length of Stay (ward) 6.37 42 4.93 137 0.097
Transferred from ward to ICU 1.83 7 1.77 32 0.383
Discharged home from ward 1.19 34 1.46 75 0.002
Discharged home from ICU 1.95 2 1.82 25 0.034
*: Two-sided student t-test for the mean length of stay in days
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saves cost as always demonstrated [34]. Needless 
to stress on the fact that cost saving is of a para-
mount priority for resources-limited countries. 
No differences were noted for transferring pa-
tients from the ward to the ICU between the two 
groups (P = 0.383), this highlights the safety of de-
escalation, and the patients’ likelihood to become 
sicker and being transferred to the ICU is the same 
in both groups. Our study was not APACH II or SOFA 
score adjusted, however, comparisons of many con-
founders were not significantly different between 
the two groups (Table 1), this may contribute to 
some robustness of our results. A point to consider 
is that the data were not segregated into teaching 
versus not teaching hospital. Another point to consi-
der is the Hawthorne phenomena effect; our study 
though it was observational, but it was monitored 
by residents and clinical pharmacist who suggested 
and observed and phoned the attending physicians 
for their prescribing practices, this may have added 
to the improved de-escalation rates [35], this would 
invite the heath care administrators to seriously im-
plement methods and procedures in this regard 
as education alone may had not been enough. In 
conclusion, the de-escalation rates improved signi-
ficantly over time with added benefits of shorter 
ICU stay, cost saving and less in-hospital mortality. 
Furthermore, escalating antimicrobial therapy was 
not associated with a better outcome.
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